Vol 58, No 4 (2007)
Review paper
Published online: 2007-05-17
Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly
Endokrynol Pol 2007;58(4):350-353.
Abstract
Consensus statement of the Polish Society of Endocrinology, regarding presurgical somatostatin analogs in acromegaly
has been presented. It is suggested to administer depot somatostatin analog (Octreotide LAR at the dose 20 mg and then
30 mg or equivalent doses of Lanreotide Autogel 90/120 mg every 4 weeks) in order to normalize or suppress to a maximal
extent GH and IGF-1 concentrations. The period of therapy in case of microadenoma would be at least 3 months (targets:
biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction, inhibition of tumor growth).
The period of therapy in case of macroadenoma would be at least 6 months, until maximal possible reduction of GH and
IGF-1 concentrations (targets: tumor shrinkage, biochemical improvement, reduced risk of disease’s complications, perioperative risk reduction). Using an uniform approach in a group, as numerous as possible, of treated patients would allow
objective evaluation of long-term efficacy of the treatment.
(Pol J Endocrinol 2007; 58 (4): 350-355)
(Pol J Endocrinol 2007; 58 (4): 350-355)
Keywords: acromegalysomatostatin analogspreparation to the surgery
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)